Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Swedish Orphan Biovitrum AB (publ) stock

SOBI.ST
SE0000872095
A0LA5K

Price

316.80
Today +/-
-0.38
Today %
-1.38 %

Swedish Orphan Biovitrum AB (publ) stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Swedish Orphan Biovitrum AB (publ) stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Swedish Orphan Biovitrum AB (publ) stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Swedish Orphan Biovitrum AB (publ) stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Swedish Orphan Biovitrum AB (publ)'s market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Swedish Orphan Biovitrum AB (publ) Stock Price History

DateSwedish Orphan Biovitrum AB (publ) Price
1/8/2025316.80 undefined
1/7/2025321.20 undefined
1/3/2025318.80 undefined
1/2/2025322.80 undefined
12/30/2024317.40 undefined
12/27/2024317.80 undefined
12/23/2024310.80 undefined
12/20/2024310.40 undefined
12/19/2024305.80 undefined
12/18/2024310.40 undefined
12/17/2024310.60 undefined
12/16/2024317.00 undefined
12/13/2024315.20 undefined
12/12/2024316.20 undefined
12/11/2024317.00 undefined
12/10/2024314.40 undefined

Swedish Orphan Biovitrum AB (publ) Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Swedish Orphan Biovitrum AB (publ), a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Swedish Orphan Biovitrum AB (publ) from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Swedish Orphan Biovitrum AB (publ)’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Swedish Orphan Biovitrum AB (publ). Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Swedish Orphan Biovitrum AB (publ)’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Swedish Orphan Biovitrum AB (publ)’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Swedish Orphan Biovitrum AB (publ)’s growth potential.

Swedish Orphan Biovitrum AB (publ) Revenue, EBIT and net profit per share

DateSwedish Orphan Biovitrum AB (publ) RevenueSwedish Orphan Biovitrum AB (publ) EBITSwedish Orphan Biovitrum AB (publ) Net Income
2029e41.26 B undefined11.45 B undefined7.42 B undefined
2028e37.52 B undefined10.14 B undefined8.68 B undefined
2027e34.58 B undefined9.18 B undefined9.7 B undefined
2026e32.38 B undefined9.96 B undefined7.82 B undefined
2025e28.81 B undefined7.65 B undefined5.7 B undefined
2024e26.99 B undefined5.65 B undefined3.75 B undefined
202322.12 B undefined4.68 B undefined2.41 B undefined
202218.79 B undefined4.52 B undefined2.64 B undefined
202115.53 B undefined3.79 B undefined2.68 B undefined
202015.26 B undefined4.46 B undefined3.25 B undefined
201914.25 B undefined4.5 B undefined3.3 B undefined
20189.14 B undefined3.13 B undefined2.42 B undefined
20176.51 B undefined1.65 B undefined1.15 B undefined
20165.2 B undefined1.13 B undefined801 M undefined
20153.23 B undefined148.85 M undefined64.91 M undefined
20142.61 B undefined-328.45 M undefined-267.83 M undefined
20132.18 B undefined-70 M undefined-93 M undefined
20121.92 B undefined-17.5 M undefined-100.9 M undefined
20111.91 B undefined-240.1 M undefined17.9 M undefined
20101.91 B undefined77.4 M undefined-104.5 M undefined
20091.3 B undefined48.3 M undefined32.4 M undefined
20081.14 B undefined-38.9 M undefined-335.4 M undefined
20071.26 B undefined55.1 M undefined79 M undefined
20061.2 B undefined54.6 M undefined92.7 M undefined
2005936.6 M undefined22.1 M undefined261.6 M undefined
2004645.3 M undefined-273.9 M undefined-26.5 M undefined

Swedish Orphan Biovitrum AB (publ) Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0.591.31.660.650.941.21.261.141.31.911.911.922.182.613.235.26.519.1414.2515.2615.5318.7922.1226.9928.8132.3834.5837.5241.26
-122.0127.36-61.0745.1228.314.58-9.2413.7746.950.210.6813.1619.7623.8361.2625.1040.3755.927.111.7621.0017.7422.006.7512.406.788.519.97
55.4665.9563.0761.5571.0575.5272.2176.7571.0164.0650.9954.0859.0159.3662.1670.1471.5273.5776.5978.8777.5676.5177.6263.6259.6053.0249.6645.7641.62
0.330.861.050.40.670.910.910.880.921.220.971.041.281.552.013.654.666.7210.9112.0412.0514.3817.17000000
-0.41-0.040.37-0.030.260.090.08-0.340.03-0.10.02-0.1-0.09-0.270.060.81.152.423.33.252.682.642.413.755.77.829.78.687.42
--91.46-1,154.29-107.05-1,103.85-64.75-14.13-524.05-109.55-425.00-116.35-688.24-7.00187.10-123.971,151.5643.32110.5436.70-1.79-17.44-1.53-8.6855.5452.0137.2024.16-10.51-14.52
116.8116.8116.8116.8116.811252.352.156.8222.1242.1265.2265.3266.16267.28269.22270270.6294.53311.61310.73312.46325.97000000
-----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Swedish Orphan Biovitrum AB (publ) Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Swedish Orphan Biovitrum AB (publ) is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (B)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                             
0.880.941.611.591.620.90.760.460.310.040.220.460.520.520.90.791.4830.740.41.051.360.9
0.30.190.090.140.080.050.10.080.110.320.310.340.530.530.520.771.462.074.14.063.765.586.46
25593830784932343363504161.856267.5848763.9692.74530465345558602
0.510.190.070.080.130.160.090.590.581.070.890.70.760.760.780.871.051.281.773.053.423.333.87
102105641231411321521352577717511405852.33-1102.05153.89189188204376831
1.821.481.861.962.051.31.131.291.281.571.651.661.881.942.322.914.166.67.328.178.7811.2112.67
634511502435301262290216252251156126115.23115112.68121134.18136.3518534493274251
000000034103101142.8631.7913635.1655.4450179199121142
000000000000000000003455580
00.010.010.010.360.430.4611.133.623.282.932.692.694.235.254.898.630.7332.9232.1433.0150.48
000000.040.040.030.031.61.611.611.551.551.551.551.551.556.685.876.297.019.64
000161442291212120024.417097.220131.43230.83355611767878843
0.630.520.510.460.680.780.821.291.535.55.054.664.394.4467.066.7510.5838.3440.1240.2341.8461.36
2.461.992.372.422.732.081.952.582.817.076.76.326.276.378.319.9710.917.1845.6648.2849.0153.0574.03
                                             
242424242425252728118147148148.36149149.150149.53149.97165167169170194
00000.81.031.031.221.264.274.844.824.874.884.9305.025.079.79.829.9510.2116.55
1.741.72.072.050.890.320.390.040.06-0.04-0.03-0.13-0.25-0.51-0.4201.533.967.2710.4813.1515.7918.05
0000000000000005.370-0.14-0.2-0.25-0.070.41-0.85
000000000000000000000-56-82
1.761.732.12.081.711.381.451.281.354.344.964.844.774.524.665.376.79.0416.9320.2123.226.5333.87
0.150.160.080.130.110.140.140.140.240.290.290.10.240.240.1800.360.490.680.570.561.251.02
0.270.110.170.20.40.30.250.170.310.20.320.30.320.450.5501.121.613.043.934.975.255.25
0.0200.020.020.10.030.020.160.20.110.070.110.060.060.591.760.894.851.921.821.352.423.86
0000000000000000000002.073.89
0000000000.16000000000.14.131.883.865.07
0.440.270.280.340.610.470.410.470.750.760.680.510.620.751.321.762.366.955.7410.448.7614.8619.1
00000000.40.291.020.700.820.820.80.50.01016.4610.459.023.1711.52
00000.090.090.080.050.050.760.350.320.30.270.3100.670.663.733.463.613.86.68
0.260000.320.1400.380.370.190.010.650.010.011.222.351.160.532.83.734.074.152.86
0.260000.410.230.090.820.71.971.060.971.131.12.332.851.841.1922.9917.6316.711.1121.07
0.690.270.280.341.020.70.51.291.452.731.741.481.741.853.654.614.28.1428.7328.0825.4625.9740.16
2.461.992.372.422.732.081.952.582.817.076.76.326.516.378.319.9710.917.1845.6648.2848.6652.574.03
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Swedish Orphan Biovitrum AB (publ) provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Swedish Orphan Biovitrum AB (publ)'s financial health and stability.

Assets

Swedish Orphan Biovitrum AB (publ)'s assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Swedish Orphan Biovitrum AB (publ) must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Swedish Orphan Biovitrum AB (publ) after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Swedish Orphan Biovitrum AB (publ)'s financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-0.41-0.040.37-0.030.180.090.08-0.340.03-0.10.02-0.1-0.09-0.270.060.81.152.423.34.223.33.322.95
000.090.080.120.070.070.270.110.360.280.450.3100.320.4400.481.592.022.012.423.2
-200-2000-300-26-394-23-460121650-1034110000
81-56252-62-113-201-169-49410-464-153719-6595-299-98-250-1,665-1,360-334-1,480-1,802
40110143-199-240-53-586-932521937-232514-765282-458-546503316118
128000000113451060605601318114032400
00000000000000.010.0200.030.510.520.921.120.670.64
0.070.010.76-0.21-0.06-0.09-0.03-0.510.06-0.220.10.410.190.230.510.341.332.093.634.935.474.584.47
-65-93-85-77-173-154-139-205-158-122-15-68-410-183-146-165-139-577-9,746-3,852-370-1,477-4,943
-253325-153-11769-17514-20-39-1,884-43-67-404-183-143-158-138-575-21,685-3,964-367-1,477-21,904
-188419-68-39242-21154185119-1,761-281502702-11,939-11230-16,961
00000000000000000000000
0.01-0.26000000.4-0.050.47-0.47-0.10.20.020-0.33-0.5-015.78-1.57-4.12-2.5511.09
0.780000-0.1400.020.031.410.5900.010.010.020.02000000.096.13
0.88-0.26000-0.4200.42-0.021.880.12-0.10.210.020.02-0.31-0.5-015.78-1.28-4.47-2.917.01
870000-282000000000-100-1288-351-438-203
00000000000000000000000
0.690.080.6-0.330.01-0.68-0.01-0.110-0.220.180.24-0.010.070.38-0.120.691.52-2.26-0.330.640.32-0.46
4.3-83.8670-286.8-234-242.5-165.3-711.8-99.8-337.987.6337.2-224.850.63361.11781,193.51,512.4-6,1121,0745,1003,099-473
00000000000000000000000

Swedish Orphan Biovitrum AB (publ) stock margins

The Swedish Orphan Biovitrum AB (publ) margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Swedish Orphan Biovitrum AB (publ). The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Swedish Orphan Biovitrum AB (publ).

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Swedish Orphan Biovitrum AB (publ)'s sales revenue. A higher gross margin percentage indicates that the Swedish Orphan Biovitrum AB (publ) retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Swedish Orphan Biovitrum AB (publ)'s earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Swedish Orphan Biovitrum AB (publ)'s total revenue generated. When comparing the revenue margin year over year, investors can gauge the Swedish Orphan Biovitrum AB (publ)'s growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Swedish Orphan Biovitrum AB (publ). Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Swedish Orphan Biovitrum AB (publ)'s financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Swedish Orphan Biovitrum AB (publ) Margin History

Swedish Orphan Biovitrum AB (publ) Gross marginSwedish Orphan Biovitrum AB (publ) Profit marginSwedish Orphan Biovitrum AB (publ) EBIT marginSwedish Orphan Biovitrum AB (publ) Profit margin
2029e77.62 %27.75 %17.99 %
2028e77.62 %27.03 %23.14 %
2027e77.62 %26.55 %28.06 %
2026e77.62 %30.74 %24.13 %
2025e77.62 %26.55 %19.77 %
2024e77.62 %20.95 %13.88 %
202377.62 %21.14 %10.89 %
202276.51 %24.06 %14.04 %
202177.56 %24.39 %17.25 %
202078.87 %29.24 %21.26 %
201976.59 %31.58 %23.19 %
201873.57 %34.23 %26.46 %
201771.52 %25.39 %17.64 %
201670.14 %21.77 %15.39 %
201562.17 %4.61 %2.01 %
201459.37 %-12.6 %-10.27 %
201358.99 %-3.22 %-4.27 %
201254.1 %-0.91 %-5.25 %
201151 %-12.57 %0.94 %
201064.04 %4.06 %-5.48 %
200971.03 %3.72 %2.5 %
200876.79 %-3.41 %-29.41 %
200772.25 %4.39 %6.29 %
200675.54 %4.55 %7.72 %
200571.1 %2.36 %27.93 %
200461.52 %-42.45 %-4.11 %

Swedish Orphan Biovitrum AB (publ) Stock Sales Revenue, EBIT, Earnings per Share

The Swedish Orphan Biovitrum AB (publ) earnings per share therefore indicates how much revenue Swedish Orphan Biovitrum AB (publ) has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Swedish Orphan Biovitrum AB (publ) earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Swedish Orphan Biovitrum AB (publ)'s earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Swedish Orphan Biovitrum AB (publ)’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Swedish Orphan Biovitrum AB (publ)'s prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Swedish Orphan Biovitrum AB (publ) Revenue, EBIT and net profit per share

DateSwedish Orphan Biovitrum AB (publ) Sales per ShareSwedish Orphan Biovitrum AB (publ) EBIT per shareSwedish Orphan Biovitrum AB (publ) Earnings per Share
2029e115.9 undefined0 undefined20.85 undefined
2028e105.4 undefined0 undefined24.39 undefined
2027e97.13 undefined0 undefined27.26 undefined
2026e90.97 undefined0 undefined21.95 undefined
2025e80.93 undefined0 undefined16 undefined
2024e75.81 undefined0 undefined10.53 undefined
202367.87 undefined14.34 undefined7.39 undefined
202260.14 undefined14.47 undefined8.44 undefined
202149.98 undefined12.19 undefined8.62 undefined
202048.97 undefined14.32 undefined10.41 undefined
201948.38 undefined15.28 undefined11.22 undefined
201833.77 undefined11.56 undefined8.93 undefined
201724.11 undefined6.12 undefined4.25 undefined
201619.33 undefined4.21 undefined2.98 undefined
201512.08 undefined0.56 undefined0.24 undefined
20149.79 undefined-1.23 undefined-1.01 undefined
20138.2 undefined-0.26 undefined-0.35 undefined
20127.25 undefined-0.07 undefined-0.38 undefined
20117.89 undefined-0.99 undefined0.07 undefined
20108.58 undefined0.35 undefined-0.47 undefined
200922.83 undefined0.85 undefined0.57 undefined
200821.89 undefined-0.75 undefined-6.44 undefined
200724.02 undefined1.05 undefined1.51 undefined
200610.72 undefined0.49 undefined0.83 undefined
20058.02 undefined0.19 undefined2.24 undefined
20045.52 undefined-2.35 undefined-0.23 undefined

Swedish Orphan Biovitrum AB (publ) business model

Swedish Orphan Biovitrum AB (Sobi) is a Swedish biotechnology company specializing in rare diseases. It was founded in 1986 as Swedish Orphan International and renamed Swedish Orphan Biovitrum AB (Sobi) in 2007. Sobi is headquartered in Stockholm and is listed on NASDAQ OMX Stockholm. Its business model focuses on developing and marketing therapies for rare diseases with limited treatment options. Sobi operates in Europe, the Middle East, North Africa, and North America, collaborating closely with patient organizations and medical professionals to raise awareness of rare diseases and provide patients with access to important therapies. The company is divided into three business areas: Hemophilia, Inflammatory Diseases, and Genetic Diseases. Sobi offers medications for bleeding disorders, inflammatory diseases, and lysosomal storage diseases, among others. Some of its key products include Elocta and Alprolix for Hemophilia A and B, Kineret for autoinflammatory diseases, Synagis for respiratory syncytial virus (RSV) infections in children, Vimizim for mucopolysaccharidosis type IVA, and Orfadin for hereditary tyrosinemia type 1. In conclusion, Sobi is a leading biotechnology company dedicated to developing and marketing therapies for rare diseases, with a wide range of products in its portfolio. It collaborates with patient organizations and strives to improve the quality of life for patients with rare diseases. Swedish Orphan Biovitrum AB (publ) is one of the most popular companies on Eulerpool.com.

Swedish Orphan Biovitrum AB (publ) SWOT Analysis

Strengths

Swedish Orphan Biovitrum AB (publ) holds several strengths that contribute to its success in the market. These strengths include:

  • Strong reputation and brand recognition in the pharmaceutical industry.
  • Diverse portfolio of orphan drugs catering to rare diseases, providing a competitive edge.
  • Robust research and development capabilities, leading to innovative drug development.
  • Established partnerships and collaborations with healthcare professionals and organizations.
  • Efficient supply chain management ensuring timely delivery of products.
  • Well-established presence in key international markets, resulting in a global customer base.

Weaknesses

Despite its strengths, Swedish Orphan Biovitrum AB (publ) also faces certain weaknesses that hinder its progress. These weaknesses include:

  • Dependence on a limited number of products for a significant portion of its revenue.
  • Relatively small scale compared to some of its competitors, impacting economies of scale.
  • Vulnerability to regulatory changes and pricing pressures in the pharmaceutical industry.
  • Challenges in securing intellectual property rights for its drug discoveries.

Opportunities

Swedish Orphan Biovitrum AB (publ) can leverage the following opportunities to expand and enhance its market position:

  • Increasing prevalence of rare diseases creates a growing market for orphan drugs.
  • Expanding into emerging markets, particularly in Asia, to tap into new customer segments.
  • Potential advancements in technology and scientific research, enabling accelerated drug development.
  • Inorganic growth opportunities through strategic acquisitions and partnerships.
  • Collaboration with research institutions and healthcare providers to strengthen R&D capabilities.

Threats

Swedish Orphan Biovitrum AB (publ) faces several threats that could hinder its growth and profitability:

  • Intense competition from large pharmaceutical companies, impacting market share.
  • Price erosion due to generic drug competition and pricing pressures from payers.
  • Stringent regulatory requirements and increasing scrutiny on drug safety and efficacy.
  • Potential disruptions in the supply chain, affecting timely delivery of products.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Swedish Orphan Biovitrum AB (publ) Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Swedish Orphan Biovitrum AB (publ) historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Swedish Orphan Biovitrum AB (publ) shares outstanding

The number of shares was Swedish Orphan Biovitrum AB (publ) in 2024 — This indicates how many shares 325.968 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Swedish Orphan Biovitrum AB (publ) earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Swedish Orphan Biovitrum AB (publ)'s earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Swedish Orphan Biovitrum AB (publ)’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Swedish Orphan Biovitrum AB (publ)'s prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Swedish Orphan Biovitrum AB (publ).

Swedish Orphan Biovitrum AB (publ) latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20242.4 4.31  (79.23 %)2024 Q3
6/30/20240.7 0.72  (3.05 %)2024 Q2
3/31/20242.42 2.67  (10.14 %)2024 Q1
12/31/20233.79 3.21  (-15.21 %)2023 Q4
9/30/20230.37 0.3  (-18.03 %)2023 Q3
6/30/20231.12 0.71  (-36.64 %)2023 Q2
3/31/20233.44 3.51  (1.96 %)2023 Q1
12/31/20224.51 4.43  (-1.79 %)2022 Q4
9/30/20221.3 1.52  (16.85 %)2022 Q3
6/30/20220.6 0.82  (37.09 %)2022 Q2
1
2
3
4
5
...
7

Eulerpool ESG Scorecard© for the Swedish Orphan Biovitrum AB (publ) stock

Eulerpool World ESG Rating (EESG©)

88/ 100

🌱 Environment

98

👫 Social

99

🏛️ Governance

68

Environment

Scope 1 - Direct Emissions
787
Scope 2 - Indirect emissions from purchased energy
619
Scope 3 - Indirect emissions within the value chain
112,957
Total CO₂ emissions
1,406
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees59
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Swedish Orphan Biovitrum AB (publ) shareholders

%
Name
Stocks
Change
Date
34.54066 % Investor AB122,964,76002/29/2024
9.84371 % AstraZeneca PLC35,043,6244,382,11212/31/2023
5.89914 % Fj¿rde AP-Fonden21,000,927-10,0002/29/2024
3.19137 % Northern Trust Investments, Inc.11,361,278-789,6292/29/2024
2.95003 % AMF Tj¿nstepension AB10,502,1032,070,6152/29/2024
2.54131 % Swedbank Robur Fonder AB9,047,0582,337,2662/29/2024
2.50804 % Handelsbanken Kapitalf¿rvaltning AB8,928,623321,8189/30/2024
2.49827 % Polar Capital LLP8,893,829-44,0408/31/2024
1.53908 % The Vanguard Group, Inc.5,479,118-939,3359/30/2024
1.14815 % Norges Bank Investment Management (NBIM)4,087,408-1,168,5636/30/2024
1
2
3
4
5
...
10

Swedish Orphan Biovitrum AB (publ) Executives and Management Board

Dr. Guido Oelkers

(58)
Swedish Orphan Biovitrum AB (publ) President, Chief Executive Officer
Compensation 47.27 M

Dr. Hakan Bjoerklund

(67)
Swedish Orphan Biovitrum AB (publ) Independent Director
Compensation 1.76 M

Ms. Helena Saxon

(53)
Swedish Orphan Biovitrum AB (publ) Director
Compensation 788,000

Mr. Staffan Schueberg

(54)
Swedish Orphan Biovitrum AB (publ) Independent Director
Compensation 677,000

Mr. Matthew Gantz

(58)
Swedish Orphan Biovitrum AB (publ) Independent Director
Compensation 673,000
1
2
3
4
...
5

Swedish Orphan Biovitrum AB (publ) Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Apellis Pharmaceuticals Stock
Apellis Pharmaceuticals
SupplierCustomer0,770,590,620,58-0,63-0,38
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals
SupplierCustomer0,770,710,880,82-0,08-0,30
Investor B Stock
Investor B
SupplierCustomer0,690,250,55-0,20-0,200,22
Sanofi Stock
Sanofi
SupplierCustomer0,540,630,620,730,020,39
Selecta Biosciences Stock
Selecta Biosciences
SupplierCustomer0,530,12-0,45-0,72-0,11-0,36
Certara Stock
Certara
SupplierCustomer0,470,610,39-0,610,37
bioMerieux Stock
bioMerieux
SupplierCustomer0,450,040,59-0,450,150,07
Morgan Stanley Stock
Morgan Stanley
SupplierCustomer0,41 -0,05-0,660,090,18
AstraZeneca Stock
AstraZeneca
SupplierCustomer0,320,350,760,840,390,68
Omnicom Stock
Omnicom
SupplierCustomer0,05-0,040,140,29-0,25-0,10
1

Most common questions regarding Swedish Orphan Biovitrum AB (publ)

What values and corporate philosophy does Swedish Orphan Biovitrum AB (publ) represent?

Swedish Orphan Biovitrum AB (publ) is committed to upholding a strong set of values and corporate philosophy. The company prioritizes patient well-being and aims to make a positive impact on the lives of individuals affected by rare diseases. Swedish Orphan Biovitrum AB (publ) embraces an open and collaborative approach, fostering innovation and learning within the healthcare industry. With a focus on delivering high-quality therapies, the company strives to be a trusted partner for patients, healthcare providers, and society as a whole. Swedish Orphan Biovitrum AB (publ) consistently demonstrates its dedication to integrity, excellence, and sustainable practices.

In which countries and regions is Swedish Orphan Biovitrum AB (publ) primarily present?

Swedish Orphan Biovitrum AB (publ) primarily operates in various countries and regions worldwide. The company has a global presence, with a significant focus on Europe. It has established a strong presence in Nordic countries such as Sweden, Norway, Denmark, and Finland. Additionally, Swedish Orphan Biovitrum AB (publ) has expanded its operations to other European countries, including the United Kingdom, Germany, France, Italy, Spain, and Switzerland. It also has a growing presence in North America, particularly in the United States and Canada. Moreover, the company is actively exploring opportunities in emerging markets to further expand its geographical footprint.

What significant milestones has the company Swedish Orphan Biovitrum AB (publ) achieved?

Swedish Orphan Biovitrum AB has accomplished several significant milestones. Notably, the company successfully launched Elocta, a treatment for hemophilia, in multiple countries. It gained regulatory approvals for Alprolix, a therapy for hemophilia B, and Orfadin, a medication for the treatment of hereditary tyrosinemia type 1. Swedish Orphan Biovitrum AB (publ) also established strategic partnerships, including collaborations with Bioverativ, Biogen, and Novimmune. Moreover, the company expanded its product pipeline through acquisitions, such as Dova Pharmaceuticals and Emalex Biosciences. These achievements solidify Swedish Orphan Biovitrum AB's position as a leader in providing innovative treatments for rare diseases.

What is the history and background of the company Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) is a multinational pharmaceutical company focused on rare diseases and specialty care. Established in 2001, it has a rich history of developing innovative therapies to address unmet medical needs. The company operates across several therapeutic areas, including hematology, immunology, and genetic diseases. Swedish Orphan Biovitrum AB (publ) collaborates with partners worldwide to advance their extensive product portfolio, leveraging their expertise to improve patients' lives. With a strong commitment to research and development, the company continues to make significant contributions to the field of healthcare. Swedish Orphan Biovitrum AB (publ) is dedicated to driving advancements in rare diseases and expanding access to life-changing treatments.

Who are the main competitors of Swedish Orphan Biovitrum AB (publ) in the market?

The main competitors of Swedish Orphan Biovitrum AB (publ) in the market include companies such as Novartis AG, Roche Holding AG, Biogen Inc., and Takeda Pharmaceutical Company Limited. These pharmaceutical companies operate in a similar market segment and represent strong competition for Swedish Orphan Biovitrum AB (publ).

In which industries is Swedish Orphan Biovitrum AB (publ) primarily active?

Swedish Orphan Biovitrum AB (publ) is primarily active in the pharmaceutical industry.

What is the business model of Swedish Orphan Biovitrum AB (publ)?

The business model of Swedish Orphan Biovitrum AB (publ) focuses on developing and commercializing innovative treatments for rare diseases. The company specializes in providing therapies that address unmet medical needs, primarily within the areas of hematology, immunology, and genetic diseases. Swedish Orphan Biovitrum AB (publ) engages in extensive research and development efforts to create effective and safe drugs for patients, collaborating with various partners in the healthcare industry. By prioritizing rare diseases and leveraging its expertise, Swedish Orphan Biovitrum AB (publ) aims to improve the lives of patients worldwide through its specialized treatments.

What is the P/E ratio of Swedish Orphan Biovitrum AB (publ) 2025?

The Swedish Orphan Biovitrum AB (publ) P/E ratio is 18.13.

What is the P/S ratio of Swedish Orphan Biovitrum AB (publ) 2025?

The Swedish Orphan Biovitrum AB (publ) P/S ratio is 3.58.

What is the Quality Investing of Swedish Orphan Biovitrum AB (publ)?

The Quality Investing for Swedish Orphan Biovitrum AB (publ) is 3/10.

What is the revenue of Swedish Orphan Biovitrum AB (publ) 2025?

The expected Swedish Orphan Biovitrum AB (publ) revenue is 28.81 B SEK.

How high is the profit of Swedish Orphan Biovitrum AB (publ) 2025?

The expected Swedish Orphan Biovitrum AB (publ) profit is 5.7 B SEK.

What is the business model of Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB is a biopharmaceutical company specializing in rare diseases and specialty medicines. It is divided into three main business areas: coagulation disorders, immunology, and genetics. The company develops, manufactures, markets, and distributes medications for these rare diseases. The coagulation disorders division focuses on products for the treatment of hemophilia, thrombosis prevention, and bleeding. The immunology division focuses on products for the treatment of rare diseases such as hereditary angioedema and primary immune thrombocytopenia. The genetics division focuses on products for the treatment of rare genetic diseases such as Gaucher's disease, Fabry disease, and Pompe disease. The company distributes its products globally and works closely with patient organizations and healthcare providers to ensure access to medication and information for patients with rare diseases. The company also invests heavily in research and development for new therapies and diagnostic procedures for rare diseases. The business model of Swedish Orphan Biovitrum is based on the production and marketing of specialty medicines for the treatment of rare diseases. It focuses on niche markets where it has strong expertise and collaborates with patient organizations and healthcare providers to meet patient needs. The company achieves high value creation and builds a differentiated competitive advantage by focusing on rare diseases.

What is the Swedish Orphan Biovitrum AB (publ) dividend?

Swedish Orphan Biovitrum AB (publ) pays a dividend of 0 SEK distributed over payouts per year.

How often does Swedish Orphan Biovitrum AB (publ) pay dividends?

The dividend cannot currently be calculated for Swedish Orphan Biovitrum AB (publ) or the company does not pay out a dividend.

What is the Swedish Orphan Biovitrum AB (publ) ISIN?

The ISIN of Swedish Orphan Biovitrum AB (publ) is SE0000872095.

What is the Swedish Orphan Biovitrum AB (publ) WKN?

The WKN of Swedish Orphan Biovitrum AB (publ) is A0LA5K.

What is the Swedish Orphan Biovitrum AB (publ) ticker?

The ticker of Swedish Orphan Biovitrum AB (publ) is SOBI.ST.

How much dividend does Swedish Orphan Biovitrum AB (publ) pay?

Over the past 12 months, Swedish Orphan Biovitrum AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Swedish Orphan Biovitrum AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of Swedish Orphan Biovitrum AB (publ)?

The current dividend yield of Swedish Orphan Biovitrum AB (publ) is .

When does Swedish Orphan Biovitrum AB (publ) pay dividends?

Swedish Orphan Biovitrum AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) paid dividends every year for the past 0 years.

What is the dividend of Swedish Orphan Biovitrum AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Swedish Orphan Biovitrum AB (publ) located?

Swedish Orphan Biovitrum AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von Swedish Orphan Biovitrum AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Swedish Orphan Biovitrum AB (publ) from 1/8/2025 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 1/8/2025.

When did Swedish Orphan Biovitrum AB (publ) pay the last dividend?

The last dividend was paid out on 1/8/2025.

What was the dividend of Swedish Orphan Biovitrum AB (publ) in the year 2024?

In the year 2024, Swedish Orphan Biovitrum AB (publ) distributed 0 SEK as dividends.

In which currency does Swedish Orphan Biovitrum AB (publ) pay out the dividend?

The dividends of Swedish Orphan Biovitrum AB (publ) are distributed in SEK.

All fundamentals about Swedish Orphan Biovitrum AB (publ)

Our stock analysis for Swedish Orphan Biovitrum AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Swedish Orphan Biovitrum AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.